The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-sense nucleotide-based compositions. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Anti-sense nucleotide-based compositions is a key innovation area in the pharmaceutical industry

Anti-sense oligonucleotides are small DNA or RNA pieces with the capability to interact with specific RNA molecules. The interaction hinders the ability of RNA to make a protein or conduct other functions. Anti-sense oligonucleotides can be utilised for inhibiting the production of proteins required for cell growth. They are being studied in the treatment of several types of cancers and other diseases.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 80+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-sense nucleotide-based compositions.

Key players in anti-sense nucleotide-based compositions – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to anti-sense nucleotide-based compositions

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Ionis Pharmaceuticals 1066 Unlock Company Profile
F. Hoffmann-La Roche 270 Unlock Company Profile
Alnylam Pharmaceuticals 242 Unlock Company Profile
Nippon Shinyaku 129 Unlock Company Profile
Regulus Therapeutics 125 Unlock Company Profile
Sanofi 117 Unlock Company Profile
Sarepta Therapeutics 103 Unlock Company Profile
Nogra Two 88 Unlock Company Profile
ProQR Therapeutics 75 Unlock Company Profile
Cold Spring Harbor Laboratory 75 Unlock Company Profile
Wave Life Sciences 73 Unlock Company Profile
Biogen 69 Unlock Company Profile
Centre National de la Recherche Scientifique 62 Unlock Company Profile
Novo Nordisk Foundation 58 Unlock Company Profile
Arbutus Biopharma 58 Unlock Company Profile
Bio-Path Holdings 54 Unlock Company Profile
Pfizer 46 Unlock Company Profile
Replicor 44 Unlock Company Profile
Daiichi Sankyo 41 Unlock Company Profile
OPKO Health 38 Unlock Company Profile
Scholar Rock Holding 33 Unlock Company Profile
Bristol-Myers Squibb 33 Unlock Company Profile
Biomarin Technologies 30 Unlock Company Profile
Neurovision Pharma 30 Unlock Company Profile
Merck & Co 29 Unlock Company Profile
Avidity Biosciences 28 Unlock Company Profile
Arrowhead Pharmaceuticals 27 Unlock Company Profile
Mitsubishi Chemical Group 25 Unlock Company Profile
Bonac 22 Unlock Company Profile
General Hospital 20 Unlock Company Profile
EdiGene 19 Unlock Company Profile
Silence Therapeutics 18 Unlock Company Profile
National Center of Neurology and Psychiatry 18 Unlock Company Profile
Kirin Holdings 17 Unlock Company Profile
Centre Leon Berard 16 Unlock Company Profile
Nissan Chemical 16 Unlock Company Profile
AptaBio Therapeutics 16 Unlock Company Profile
Institut de Myologie 16 Unlock Company Profile
Dynavax Technologies 16 Unlock Company Profile
Viridian Therapeutics 16 Unlock Company Profile
Massachusetts General Hospital 16 Unlock Company Profile
Nationwide Children's Hospital 16 Unlock Company Profile
City of Hope 15 Unlock Company Profile
Erasmus MC 15 Unlock Company Profile
Wings Therapeutics 14 Unlock Company Profile
Johnson & Johnson 14 Unlock Company Profile
Samjin Pharm 13 Unlock Company Profile
OPKO CURNA 13 Unlock Company Profile
Lipigon Pharmaceuticals 12 Unlock Company Profile
Danaher 12 Unlock Company Profile

Source: GlobalData Patent Analytics

Ionis Pharmaceuticals (Ionis), formerly ISIS Pharmaceuticals, is one of the leading patent filers in nucleic acid active pharmaceutical ingredient and focuses on the discovery and development of RNA-targeted drugs. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy, and Waylivra for familial chylomicronemia syndrome. Ionis develops products based on its proprietary antisense technology.

In terms of application diversity, OPKO CURNA is the top company, followed by Neurovision Pharma and Replicor. By means of geographic reach, Neurovision Pharma holds the top position. Pfizer and AptaBio Therapeutics are in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.